Relaxin prevents the development of severe acute pancreatitis

Table 5 Order of groups according to the increase in the severity degree

GROUP NR.	GROUP DESCRIPTION
1	Basal Reference Control
2	Surgery Control
12	Relaxin administered 12h & 1h pre- BPDOE-CDLs and 4h post-BPDOE-CDLs
10	Relaxin administered 1h pre- BPDOE-CDLs and 4h post-BPDOE-CDLs
8	Relaxin administered 1h pre-BPDOE-CDLs
9	Relaxin administeres 1h post-BPDOE-CDLs
11	Relaxin administered 4h post-BPDOE-CDLs
5	Relaxin and L-NAME administered 1h pre- BPDOE-CDLs and 4h post-BPDOE-CDLs
6	Relaxin and Mifepristone administered 1h pre- BPDOE-CDLs and 4h post-BPDOE-CDLs
7	Relaxin, L-NAME & Mifepristone administered 1h pre- BPDOE-CDLs and 4h post-BPDOE-CDLs
3	BPDOE-CDLs AP model
4	Vehicle (PBS) control

The BPDOE-CDLs model induces a severe AP (group 3).Prophylactic treatment with relaxin, as shown for groups10&12, markedly reduces the severity of the pathology, being still useful although in a lesser degree even after AP was triggered.